Premium
Sustained Protein Release from a Core‐Shell Drug Carrier System Comprised of Mesoporous Nanoparticles and an Injectable Hydrogel
Author(s) -
Manavitehrani Iman,
Fathi Ali,
Schindeler Aaron,
Dehghani Fariba
Publication year - 2018
Publication title -
macromolecular bioscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 105
eISSN - 1616-5195
pISSN - 1616-5187
DOI - 10.1002/mabi.201800201
Subject(s) - nanoparticle , mesoporous material , mesoporous silica , bovine serum albumin , biomaterial , drug delivery , drug carrier , controlled release , chemical engineering , materials science , chemistry , bone morphogenetic protein 2 , nanotechnology , biocompatible material , biomedical engineering , chromatography , organic chemistry , biochemistry , in vitro , medicine , engineering , catalysis
The manufacture of a biocompatible carrier for controlled delivery of bioactive compounds is described. This carrier is composed of a mesoporous silica nanoparticle as core that is homogenously distributed in an injectable hydrogel. For the synthesis of nanoparticles, a one step sol‐gel method is developed to produce pores with the range of 100 nm. BMP2 and Fluorescein‐conjugated bovine serum albumin is used as proteinaceous agents for measuring release, and is loaded into mesoporous silica nanoparticles at the optimum conditions of 48 h incubation period using 1:10 ratio of protein to nanoparticles. The release of proteins from either mesoporous nanoparticles or hydrogel individually involves a burst release stage, however the release from the core/shell carrier designed in this study follows a zero order kinetic. In summary, this biomaterial may be favorable for delivery of bioactive compounds such as BMP2 for a range of applications including bone tissue regeneration.